SCHEMBL14734700

SCHEMBL14734700

CC(C)(CNc1ccc(-c2ccc3nc(O)[nH]c3c2)nn1)c1ncccc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.34
CDC7 O00311 2/20 0.34
ROCK2 O75116 2/20 0.34
PIM1 P11309 2/20 0.34
PRKACA P17612 2/20 0.34
CDK2 P24941 2/20 0.34
GSK3B P49841 2/20 0.34
HIPK2 Q9H2X6 2/20 0.34
MAPK14 Q16539 2/20 0.34
DAPK3 O43293 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
PAK4 O96013 1/20 0.34
FLT3 P36888 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK8 P49336 1/20 0.34
CLK2 P49760 1/20 0.34
CDK7 P50613 1/20 0.34
CDK9 P50750 1/20 0.34
PRKX P51817 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14990934 0.94 CDC7 (0.33) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL18470820 0.83 IL1B (0.33) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL12287621 0.80 TGFBR1 (0.48) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL12287071 0.79 PDPK1 (0.45) CDK2JAK3
SCHEMBL12287609 0.78 ALOX5AP (0.39) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL21170097 0.77 CDC7 (0.33) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL12287966 0.77 GP6 (0.39)
SCHEMBL21170329 0.76 IL1B (0.34) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL12286826 0.76 PDE4A (0.38)
SCHEMBL21170249 0.76 IL1B (0.33) CDC7ROCK2PIM1PRKACACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 US claimed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 US claimed
US-10076519-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2018-09-18 US disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 US disclosed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 US disclosed
EP-2563365-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE Cytokinetics, Inc. (US) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS MUSK, PYGM, GYS1 TRPV1 3053/4885CDC7 4645/4885ROCK2 1559/4885
US-10076519-B2 Substituted pyridazines as skeletal muscle modulators MUSK, PYGM, GYS1 TRPV1 3053/4885CDC7 4645/4885ROCK2 1559/4885
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE SLC7A1, F12, C5 TRPV1 3203/4885CDC7 3755/4885ROCK2 2326/4885
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE SLC7A1, F12, C5 TRPV1 3200/4885CDC7 3691/4885ROCK2 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.